

SOHO Central Europe 2026

FRIDAY: MPN, AML, MDS, CLL & Lymphoma			
SESSION I MPN & CML October 9, Friday, 09:30-11:10 Chair: A. Hussain & J. Apperley			
09:30	Opening remarks		
09:40	When the Guidelines don't Help!	Jane Apperley	Hammersmith, UK
09:55	Why, when and in whom to stop CML treatment safely	Jiri Mayer	Masaryk Univ. Brno, CZ
10:10	Between Risk and Reality: The haemostatic problem in MPN	Alizadeh Hussain	Univ. Pécs, HU
10:25	Clinical scenarios: hemostatic challenges in MPN	Drazen Pulanic	Univ. Zagreb, HR
10:40-11:10	DISCUSSION		
SESSION II AML October 9, Friday, 11:10-12:55. Chair: Árpád Bátaí & Naval Daver			
11:10	Ven-Aza – a rising star?	Peter Farkas	Semmelweis Univ, Budapest, HU
11:25	Assessment of fitness and therapeutic options in unfit AML patients	Mirta Mikulic	Univ. Zagreb, HR
11:40	The role of HSCT for AML in first CR	Árpád Bátaí	Szt. László Hosp., HU
11:55	Managing FLT3 mutant AML	Gabriel Ghiaur	Hopkins/Bucharest, RO / USA
12:10	Management of AML in patients unfit for aggressive treatment	Matevž Škerget	Med. Center Ljubljana, SL
12:25-12:55	DISCUSSION		
13:00	SYMPOSIUM 13:20 – 14:20		
SESSION III CLL October 9, Friday, 14:20-16:05. Chair: Róbert Szász & Othman Al-Sawaf			
14:20	First-line continuous therapies	Othman Al-Sawaf	Univ.Cologne, D
14:35	First-line, fixed-duration therapies	Róbert Szász	Univ Debrecen, HU
14:50	Prophylaxis of infectious complications in CLL	Iwona Hus	Univ.Lublin, Poland
15:05	The Richter transformation; are there any changes in 2026?	Sandra Basic-Kinda	Univ. Zagreb, HR
15:20	Treatment of CLL in the near future	Michael Doubek	Univ. Hosp. Brno, Cz
15:35-16:05	DISCUSSION		
SESSION IV MDS October 9, Friday, 16:05-17:50. Chair: Viktor Lakatos & Varun Mehra			
16:05	Updates in diagnostics/immunobiological understanding and impact of prognostic scoring in decision making	Varun Mehra	Kings College Hosp. London
16:20	Non-transplant treatment strategies of high-risk MDS	Inga Mandac-Smoljanovic	Merkur Hosp., Zagreb, HR
16:35	Pre- and post-transplant strategies to improve outcomes of HSCT for MDS	Viktor Lakatos	St. László Hosp. HU
16:50	HSCT in MDS, indications, outcomes, strategies	Alina Tanase	Instit. Clinic Fundeni, Bucharest, RO
17:05	Low-risk MDS therapy - advances in recent years	Anna Jonasova	Charles Univ., Prague, Cz
17:20-17:50	DISCUSSION		
17:50 Coffee break: 17:50-18:10			
SESSION V ind. NHL & MCL October 9, Friday, 18:10-19:55. Chair: A. Masszi & I. Aurer			
18:10	Treatment of HL in 2026	Igor Aurer	Univ. Zagreb, HR
18:25	Frontline therapy of MCL	Wojciech Jurczak	National Research Inst. Oncol, Krakow, PL
18:40	Frontline treatment of FL	András Masszi	Oncol Inst. Budapest, HU
18:55	Treatment landscape of R/R FL in 2026	Vít Procházka	Univ. Hosp., Olomouc, Cz
19:10	Management of R/R MCL in 2026	Pavel Klener	Charles Univ., Prague, Cz
19:25-19:55	DISCUSSION		
19:55 – 20:45 EVENING SYMPOSIUM SPONSORED BY ASTELLAS			

SATURDAY: BM failure, PNH, ALL, Cellular therapy, MM, LBCL			
SESSION VI BM failure & PNH October 10, Saturday 08:00-09:30; Chair: I.Bodó & M. Griffin			
08:00	Approach to classic PNH in 2026	Imre Bodó	Semmelweis Univ, Budapest
08:15	The failing bone marrow and PNH	Morag Griffin	St. James Hos. Leeds, UK
08:30	Severe aplastic anemia in 2026	Phil Scheinberg	Sao Jose Hosp, Sao Paulo, Brazil
08:45	HSCT for TBD-related BM failure Syndromes: Progress and challenges	Pál Szabolcs	UPMC Children's Hosp. Pittsburgh, USA
09:00-09:30	DISCUSSION		
SESSION VII ALL October 10, Saturday 09:30-11:50; Chair: Zsolt Nagy & Nicola Gökbüget			
09:30	How to improve outcome of T-ALL	Nicola Gökbüget	University of Frankfurt, D
09:45	Evolving paradigms of the treatment of adults with B-cell Ph- ALL	Sebastian Giebel	Gliwice, PL
10:00	Ph+ ALL in 2026	Zsolt Nagy	Semmelweis Univ, Budapest, HU
10:15	Supportive care in ALL	Zinaida Peric	Clinical Hosp.Ctr, Rijeka, HR
10:30-11:50	DISCUSSION		
11:50 LUNCH SYMPOSIUM 11:50 – 12:50			
SESSION VIII Cellular ther. October 10, Saturday 12:50-14:35; Chair: P. Reményi & J. DiPersio			
12:50	Can AML and T-ALL be effectively treated with CAR-T?	John DiPersio	Washington Univ. STL, MO, US
13:05	Virus-specific T-cell therapies	Krisztián Kállay	Szt.László Hosp, Budapest
13:20	Role of cellular therapies in the management of MCL	Ciprian Tomuleasa	Chiricuta Cancer Ctr, Cluj, RO
13:35	Infectious complications after CAR-T cell therapy	Lidia Gil	Medical Univ, Poznan PL
13:50	Academic/Point of Care CAR-T Cell Therapies - Focus on Europe	Matjaz Sever	Med. Center Ljubljana, SL
14:05-14:35	DISCUSSION		
SESSION IX MM October 10, Saturday 14:35-16:05; Chair: Gergely Varga & Gábor Mikala			
14:35	Current praxis: focus on engaging T-cells (bispecifics and CAR)	Roman Hajek	Univ. Hospital Ostrava, CZ
14:50	Down with Dex!	Gergely Varga	Semmelweis Univ. HU
15:05	Supportive care in multiple myeloma	Artur Jurczyszyn	Jagellonian Univ. PL
15:20	Small molecules in the Era of immune therapies	Gábor Mikala	Semmelweis Univ. HU
15:35-16:05	DISCUSSION		
COFFEE BREAK 16:05-16:25			
SESSION X LBCL October 10, Saturday, 16:25-17:55. Chair: Gergely Lajos & Marek Trněný			
16:25	First line DLBCL Therapy: Choosing Wisely	Marek Trněný	Charles Univ, Prague, CZ
16:40	Are we ready for MRD in DLBCL ?	Gergely Lajos	Univ. Debrecen, HU
16:55	Management of R/R LBCL: the future is now	Lubos Drgona	Comenius Univ, Bratislava
17:10	The role of bispecific antibodies in aggressive LBCL	Monika Długosz-Danecka	Krakow, PL
17:25-17:55	DISCUSSION		
CLOSING REMARKS			